Hypochondroplasia

11 registered clinical trials studyying Hypochondroplasia — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia NCT07393373	QED Therapeutics, a BridgeBio company	Phase 2
Recruiting	Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dy NCT07388966	SYSNAV	—
Recruiting	A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months NCT07126262	BioMarin Pharmaceutical	Phase 2
Enrolling By Invitation	Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia NCT07073014	BioMarin Pharmaceutical	Phase 3
Enrolling By Invitation	An Interventional Study of Infigratinib in Children With Hypochondroplasia NCT06873035	QED Therapeutics, a BridgeBio company	Phase 2 / Phase 3
Active Not Recruiting	Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia NCT06455059	BioMarin Pharmaceutical	Phase 3
Recruiting	Prospective Clinical Assessment Study in Children With Hypochondroplasia NCT06410976	QED Therapeutics, a BridgeBio company	—
Recruiting	A Multicenter Multinational Observational Study of Children With Hypochondroplasia NCT06212947	BioMarin Pharmaceutical	—
Recruiting	Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy) NCT05328050	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	—
Completed	C-Type Natriuretic Peptide and Achondroplasia NCT01541306	Nemours Children's Clinic	—
Completed	Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Childr NCT01111019	Merck KGaA, Darmstadt, Germany	Phase 2